For instance, 5-fluorouracil (5-FU) has been noted to augment the antitumor activity of CB-839 in PIK3CA mutant colorectal cancers [55], and the proteasome inhibitor carfilzomib has shown synergistic effects when used with CB-839 in multiple myeloma [56]. The gene discussed is PIK3CA; the disease is plasma cell myeloma.